cancer medicine and hematology
Post on 01-Jul-2015
172 Views
Preview:
TRANSCRIPT
cancer medicine and hematology
Harvard Medical School Department of Continuing Education
Earn up to 51.75 AMA PRA Crategory 1 Credits™
Sunday, September 29 - Friday, October 4, 2013at the
Fairmont Copley Plaza Hotel, Boston, MA
under the direction of Robert J. Mayer, M.D.
COURSE OVERVIEWThe continuing deluge of new clinical data on novel cancer therapies, molecular diagnostics tests, and emerging treatment approaches makes it difficult for practicing oncologists to stay current and up-to-date on the rationale behind these advances.
This intensive six-day activity is designed to provide a comprehensive review for practitioners of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic disorders. Primary emphasis will be placed upon the broad area of medical management. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids. Participants will be invited to present challenging cases to a faculty panel in a special Wednesday evening session.
Optional Maintenance of Certification (MOC) opportunity for optimum results! Attendees enrolled in ABIM’s Maintenance of Certification (MOC) course and required to earn points towards recertification may attend an optional MOC session on Tuesday evening. This session will guide you through the 2013 Update in Medical Oncology module.
LEARNER OBJECTIVESAfter participating in this program, learners will be able to:
• Evaluate, treat, and manage patients with hematologic disorders more effectively by making appropriate use of current and emerging therapies, cytological characteristics, and molecular diagnostics tests
• Improve care for breast cancer patients by incorporating novel targeted therapies and molecular diagnostics testing into current treatment paradigms
• Create multimodal treatment plans for lung, head, and neck cancers that utilize newly approved therapies and conform more closely to current expert recommendations
• Improve treatment of patients with gastrointestinal and neuroendocrine cancers with more effective uses of molecular diagnostics and available systemic therapies
• Provide care for prostate, testicular, renal, and bladder cancers that is tailored to individual patients and their risk factors and makes appropriate use of new and emerging therapie
Sunday, September 29 - Friday, October 4, 2013
cancer medicine and
hematology
www.cme.hms.harvard.edu/courses/cancermedicine
• Utilize genetic testing, novel treatment approaches, and palliative care to create optimized care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers
• Incorporate new therapies where available and new clinical trial data into management plans for a wide range of less common cancers, including brain tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma
• Provide effective supportive and palliative care by actively managing pain, depression, dementia, emesis, insomnia, infection, and other aspects of cancer and cancer treatment that can detract from patient quality of life and produce less than optimal outcomes
WHO SHOULD ATTENDMedical Oncologists, Hematologists, Radiation Oncologists, Oncology Surgeons, and Internists
ACGME COMPETENCIESThis course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:
• Patient Care
• Medical knowledge
• Practice-based learning and improvement and Interpersonal and communication skills
ACCREDITATIONThe Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 51.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 0.75 credits of Risk Management Study. This includes: 0.75 Credits of Opioid Education and Pain Management Training.
Janet L. Abrahm, M.D.Dana-Farber Cancer Institute
Jeremy S. Abramson, M.D.Massachusetts General Hospital
Kenneth C. Anderson, M.D.Dana-Farber Cancer Institute
Tracy T. Batchelor, M.D., M.P.H. Massachusetts General Hospital
Kenneth A. Bauer, M.D.Beth Israel Deaconess Medicine Center
Edward J. Benz, Jr., M.D.Dana-Farber Cancer Institute
Robert A. Brodsky, M.D.Johns Hopkins University
Harold J. Burstein, M.D., Ph.D.Dana-Farber Cancer Institute
John C. Byrd, M.D.Ohio State University
George P. Canellos, M.D.Dana-Farber Cancer Institute
Stephen A. Cannistra, M.D.Beth Israel Deaconess Medical Center
Toni K. Choueiri, M.D.Dana-Farber Cancer Institute
Jean M. Connors, M.D.Brigham and Women’s Hospital
Gilbert Daniels, M.D.Massachusetts General Hospital
Daniel J. DeAngelo, M.D., Ph.D.Dana-Farber Cancer Institute
George D. Demetri, M.D.Dana-Farber Cancer Institute
Walter H. Dzik, M.D.Massachusetts General Hospital
Mark D. Fleming, M.D., D.Phil.Boston Children’s Hospital
Arnold S. Freedman, M.D.Dana-Farber Cancer Institute
Charles S. Fuchs, M.D., M.P.H.Dana-Farber Cancer Institute
Judy E. Garber, M.D., M.P.H.Dana-Farber Cancer Institute
Levi A.Garraway, M.D., Ph.DDana-Farber Cancer Institute
James D. Griffin, M.D.Dana-Farber Cancer Institute
Robert I. Haddad, M.D.Dana-Farber Cancer Institute
Robert I. Handin, M.D.Brigham and Women’s Hospital
Matthew M. Heeney, M.D.Boston Children’s Hospital
F. Stephen Hodi, M.D.Dana-Farber Cancer Institute
Joseph O. Jacobson, M.D.Dana-Farber Cancer Institute
Bruce E. Johnson, M.D.Dana-Farber Cancer Institute
Philip W. Kantoff, M.D.Dana-Farber Cancer Institute
Joel T. Katz, M.D.Brigham and Women’s Hospital
Kenneth Kaushansky, M.D. Stony Brook University
Ian E. Krop, M.D., Ph.D.Dana-Farber Cancer Institute
Matthew H. Kulke, M.D.Dana-Farber Cancer Institute
David J. Kuter, M.D., D.Phil.Massachusetts General Hospital
Thomas J. Lynch, Jr., M.D.Yale Cancer Center
Ursula A. Matulonis, M.D.Dana-Farber Cancer Institute
Robert J. Mayer, M.D.Dana-Farber Cancer Institute
Ellis Neufeld, M.D.Boston Children’s Hospital
Peter E. Newburger, M.D.University of Massachusetts Medical School
William K. Oh, M.D.Mount Sinai School of Medicine
Geoffrey R. Oxnard, M.D. Dana-Farber Cancer Institute
Ann H. Partridge, M.D., M.P.H.Dana-Farber Cancer Institute
Geoffrey I. Shapiro, M.D., Ph.D.Dana-Farber Cancer Institute
Lawrence N. Shulman, M.D.Dana-Farber Cancer Institute
Robert J. Soiffer, M.D.Dana-Farber Cancer Institute
David P. Steensma, M.D.Dana-Farber Cancer Institute
Richard M. Stone, M.D.Dana-Farber Cancer Institute
Sapna Syngal, M.D., M.P.H.Dana-Farber Cancer Institute
Ayalew Tefferi, M.D.Mayo Clinic
Eric P. Winer, M.D.Dana-Farber Cancer Institute
Brian M. Wolpin, M.D.Dana-Farber Cancer Institute
cancer medicine and hematology
courseschedule
www.cme.hms.harvard.edu/courses/cancermedicine
SATURDAY, SEPTEMBER 28, 20136:00 pm - 9:00 pm
Evening Registration
SUNDAY, SEPTEMBER 29, 2013
Presiding: Robert J. Mayer, M.D.
7:00 am Registration
8:45 am Welcome Robert J. Mayer, M.D.
9:00 am Stem Cell Biology and Hematopoietic Growth Factors
David J. Kuter, M.D., D.Phil.
10:00 am Transfusion Medicine for the Clinician Walter H. Dzik, M.D.
11:00 am Break
11:15 am Hemolytic Anemias Jean M. Connors, M.D.
12:15 pm Bone Marrow Failure States Robert A. Brodsky, M.D., Ph.D.
1:15 pm Adjourn
Presiding: David J. Kuter, M.D., D.Phil.
2:15 pm Thrombocytopenias Kenneth Kaushansky, M.D.
3:15 pm Iron Deficiency and Iron Overload Mark D. Fleming, M.D., Ph.D.
4:00 pm Break
4:15 pm Hemoglobinopathies Matthew M. Heeney, M.D.
5:15 pm Leukocyte Disorders Peter E. Newburger, M.D.
6:15 pm Adjourn
MONDAY, SEPTEMBER 30, 2013Presiding: James D. Griffin, M.D.
8:00 am Platelet Function and von Willebrand’s Disease
Robert I. Handin, M.D.
9:00 am Hypercoagulable Syndromes and New Anticoagulant Therapies
Kenneth A. Bauer, M.D.
10:15 am Break
10:30 am Hemophilia-Related Syndromes Ellis J. Neufeld, M.D., Ph.D.
11:30 am Panel Discussion
12:00 pm Adjourn
Presiding: Bruce E. Johnson, M.D.
1:00 pm Molecular Genetics of Cancer Levi A. Garraway, M.D., Ph.D.
2:00 pm Advances in Cancer Drug Development Geoffrey I. Shapiro, M.D., Ph.D.
3:00 pm Break
3:15 pm Infections in the Immunocompromised Host Joel T. Katz, M.D.
4:00 pm Biology of Bone Marrow Transplantation Robert J. Soiffer, M.D.
5:00 pm Adjourn
cancer medicine and hematology
courseschedule
TUESDAY, OCTOBER 1, 2013
Presiding: Robert J. Soiffer, M.D.
Acute Leukemia and Myelodysplasia:
8:00 am Biology David P. Steensma, M.D.
8:45 am Treatment Richard M. Stone, M.D.
9:45 am Chronic Myelogenous Leukemia Daniel J. De Angelo, M.D., Ph.D.
10:30 am Break
10:45 am Myeloproliferative Syndromes Ayalew Tefferi, M.D.
11:30 am Plasma Cell Neoplasms Kenneth C. Anderson, M.D.
12:30 pm Panel Discussion
1:00 pm Adjourn
Presiding: Richard M. Stone, M.D.
2:00 pm Low Grade Lymphoma Jeremy S. Abramson, M.D.
2:40 pm High Grade Lymphoma Arnold S. Freedman, M.D.
3:30 pm Break
3:45 pm Hodgkin’s Disease George P. Canellos, M.D.
4:30 pm CLL and Variants John C. Byrd, M.D.
5:15 pm Panel Discussion
5:45 pm Adjourn
7:00 pm - 9:30 pm
ABIM Maintenance of Certification (MOC) Session: 2013 Update in Medical Oncology ModuleHarold J. Burstein, M.D., Ph.D.; Daniel J. DeAngelo, M.D., Ph.D.; Robert J. Mayer, M.D.
WEDNESDAY, OCTOBER 2, 2013
Presiding: Edward J. Benz, Jr., M.D.
8:00 am Neuroendocrine Tumors Matthew H. Kulke, M.D.
Gastrointestinal Malignancies:
8:30 am Genetics and Screening Sapna Syngal, M.D., M.P.H.
9:00 am Esophageal and Gastric Charles S. Fuchs, M.D., M.P.H.
9:45 am Break
10:00 am Pancreas and Hepatobiliary Brian M. Wolpin, M.D.
10:45 am Colorectal and Anal Robert J. Mayer, M.D.
11:45 am Panel Discussion
12:15 pm Adjourn
Presiding: Eric P. Winer, M.D.
1:15 pm Sarcoma and GIST George D. Demetri, M.D.
2:15 pm Mesothelioma and Thymic Tumors Geoffrey R. Oxnard, M.D.
3:00 pm Clinical Essentials of Palliative Care Janet L. Abrahm, M.D.
3:45 pm Break
Gynecologic Cancer:
4:00 pm Ovarian Stephen A. Cannistra, M.D.
5:00 pm Cervical, Endometrial, Trophoblastic Ursula A. Matulonis, M.D.
5:45 pm Panel Discussion
6:15 pm Adjourn8:00 pm - 10:00 pm
Case PresentationHarold J. Burstein, M.D., Ph.D.; George P. Canellos, M.D.; Bruce E. Johnson, M.D.; David J. Kuter, M.D., D.Phil.; Robert J. Mayer, M.D.
cancer medicine and hematology
courseschedule
THURSDAY, OCTOBER 3, 2013
Presiding: Philip W. Kantoff, M.D.
8:00 am Melanoma F. Stephen Hodi, M.D.
9:00 am Thyroid Cancer Gilbert H. Daniels, M.D.
10:00 am Break
10:15 am Head and Neck Cancer Robert I. Haddad, M.D.
Lung Cancer:
11:15 am Non-Small Cell Thomas J. Lynch, M.D.
12:10 pm Small Cell Bruce E. Johnson, M.D.
12:45 pm Panel Discussion
1:00 pm Adjourn
Presiding: Lawrence N. Shulman, M.D.
2:00 pm Neuro-Oncology Tracy T. Batchelor, M.D., M.P.H.
Genitourinary Cancer:
3:00 pm Testicular William K. Oh, M.D.
3:45 pm Break
4:00 pm Renal and Bladder Toni K. Choueiri, M.D.
4:45 pm Prostate Philip W. Kantoff, M.D.
5:45 pm Panel Discussion
6:15 pm Adjourn
7:00 pm - 10:00 pm
Dinner at the Harvard Club“Does Quality Improvement Really Enhance Cancer Care?” - Joseph O. Jacobson, M.D.
FRIDAY, OCTOBER 4, 2013
Presiding: Robert J. Mayer, M.D.
Breast Cancer:
8:00 am Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention
Judy E. Garber, M.D., M.P.H.
8:30 am Advances in Staging, Prognosis, Surgery and Radiation
Harold J. Burstein, M.D, Ph.D.
9:15 am Adjuvant and Neoadjuvant Therapy for Operable Breast Cancer
Eric P. Winer, M.D.
10:00 am Break
10:15 am Management of Metastatic Disease:
HER 2 Negative Disease Lawrence N. Shulman, M.D.
HER 2 Positive Disease Ian E. Krop, M.D., Ph.D.
11:00 am Management and Counseling of Breast Cancer Survivors
Ann H. Partridge, M.D., M.P.H.
11:30 am Panel Discussion
12:15 pm Concluding Remarks Robert J. Mayer, M.D.
12:30 pm Course AdjournPlease note: Program changes/ substitutions may be made without notice.
www.cme.hms.harvard.edu/courses/cancermedicine
THURSDAY, OCTOBER 3, 2013
Presiding: Philip W. Kantoff, M.D.
8:00 am Melanoma F. Stephen Hodi, M.D.
9:00 am Thyroid Cancer Gilbert H. Daniels, M.D.
10:00 am Break
10:15 am Head and Neck Cancer Robert I. Haddad, M.D.
Lung Cancer:
11:15 am Non-Small Cell Thomas J. Lynch, M.D.
12:10 pm Small Cell Bruce E. Johnson, M.D.
12:45 pm Panel Discussion
1:00 pm Adjourn
Presiding: Lawrence N. Shulman, M.D.
2:00 pm Neuro-Oncology Tracy T. Batchelor, M.D., M.P.H.
Genitourinary Cancer:
3:00 pm Testicular William K. Oh, M.D.
3:45 pm Break
4:00 pm Renal and Bladder Toni K. Choueiri, M.D.
4:45 pm Prostate Philip W. Kantoff, M.D.
5:45 pm Panel Discussion
6:15 pm Adjourn
7:00 pm - 10:00 pm
Dinner at the Harvard Club“Does Quality Improvement Really Enhance Cancer Care?” - Joseph O. Jacobson, M.D.
FRIDAY, OCTOBER 4, 2013
Presiding: Robert J. Mayer, M.D.
Breast Cancer:
8:00 am Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention
Judy E. Garber, M.D., M.P.H.
8:30 am Advances in Staging, Prognosis, Surgery and Radiation
Harold J. Burstein, M.D, Ph.D.
9:15 am Adjuvant and Neoadjuvant Therapy for Operable Breast Cancer
Eric P. Winer, M.D.
10:00 am Break
10:15 am Management of Metastatic Disease:
HER 2 Negative Disease Lawrence N. Shulman, M.D.
HER 2 Positive Disease Ian E. Krop, M.D., Ph.D.
11:00 am Management and Counseling of Breast Cancer Survivors
Ann H. Partridge, M.D., M.P.H.
11:30 am Panel Discussion
12:15 pm Concluding Remarks Robert J. Mayer, M.D.
12:30 pm Course AdjournPlease note: Program changes/ substitutions may be made without notice.
DISCLOSURE POLICYHarvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers, and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
REFUND POLICYA handling fee of $60 is deducted for cancellation. Refund requests must be received by postal mail, email, or fax one week prior to this activity. No refunds will be made thereafter.
COURSE LOCATIONAll sessions for this course will be held at The Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston MA 02116 (telephone: 617-267-5300).
ACCOMMODATIONS/TRAVELA limited number of rooms have been reserved at The Fairmont Copley Plaza Hotel (telephone: 617-267-5300) until September 9, 2013. Please specify that you are enrolled in this course to receive a reduced room rate of $299 per night Single/Double. Hotel arrangements can also be made online at:https://resweb.passkey.com/go/danafarber2013. Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration. For airline reservations, contact the HMS Travel Desk toll free 1-877-4-HARVMD (1-877-442-7863), Monday – Friday, 9:00 AM to8:00 PM (EST). From outside the U.S., Canada, and Virgin Islands, please call 617-559-3764.
cancer medicine and hemotology | September 29 – October 4, 2013 | course #331059
Tuition Fee: $1,500 (USD)
Print Name Clearly – All Fields Required
Full Name First Middle Initial Last
Mailing Address Street City State Zip Code
Daytime Phone ( ) Fax Number ( )
Please note: Your email address is used for critical information about the course, including registration confirmation,
evaluation, and certificate. Please be sure to include an email address you check daily or frequently.
Email Address Please check if you wish to be excluded from receiving email notices of future Harvard Medical School – Department of
Continuing Education programs.
Profession Degree
Primary Specialty (Physicians only) Board Certified: Yes No
Professional School Attended (Physicians only) Harvard Medical School U.S. Medical School
International Year of Graduation
Register early as the course fills up quickly. www.cme.hms.harvard.edu/courses/cancermedicine
cancer medicine and hematology Earn up to 51.75 AMA PRA Crategory 1 Credits™
cancer medicine and hematologySunday, September 29 - Friday, October 4, 2013
✁
Online registrants – add the first three characters of the source code found here
Source code: J W E B K L M X Z Z Z
REGISTRATION INFORMATIONTuition Fee — $1,500 (USD). Registration by credit card (VISA or MasterCard) can be made at: www.cme.hms.harvard.edu/courses/cancermedicine. Registration by check (draft on a United States bank): please make payable to Harvard Medical School and mail with registration form to Harvard Medical School- Department of Continuing Education, PO Box 417476, Boston, MA 02241-7476. Telephone and fax registration is not accepted.
Registration with cash payment is not permitted. Upon receipt of your paid registration, an email confirmation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information including: registration confirmation, evaluation, and certificate.
INQUIRIESBy telephone: 617-384-8600, Monday – Friday, 10:00 AM to 4:00 PM (EST) or by email at: hms-cme@hms.harvard.edu
ONLINE INFORMATIONTo register or view activity information online, visit www.cme.hms.harvard.edu/courses/cancermedicine.
To ensure proper registration, please add the first three characters of the source code found at the bottom of this registration form.
top related